<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Early diagnosis and detection &#8211; Birmingham Health Partners</title>
	<atom:link href="https://birminghamhealthpartners.co.uk/category/early-diagnosis-and-detection/feed/" rel="self" type="application/rss+xml" />
	<link>https://birminghamhealthpartners.co.uk</link>
	<description>Strategic clinical-academic research partnership</description>
	<lastBuildDate>Tue, 23 Jun 2026 11:51:58 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.2</generator>

<image>
	<url>https://birminghamhealthpartners.co.uk/wp-content/uploads/2018/11/cropped-BHP_Twitter-profile-400x400-32x32.jpg</url>
	<title>Early diagnosis and detection &#8211; Birmingham Health Partners</title>
	<link>https://birminghamhealthpartners.co.uk</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Drug to delay Type 1 Diabetes approved by NICE</title>
		<link>https://birminghamhealthpartners.co.uk/drug-to-delay-type-1-diabetes-approved-by-nice/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Tue, 23 Jun 2026 11:51:58 +0000</pubDate>
				<category><![CDATA[Birmingham Health Partners]]></category>
		<category><![CDATA[Early diagnosis and detection]]></category>
		<category><![CDATA[Experimental medicine]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=12037</guid>

					<description><![CDATA[Diabetes experts from across Birmingham Health Partners have welcomed the approval of teplizumab for use on the NHS, following an announcement by the National Institute for Health and Care Excellence (NICE). The immunotherapy drug can delay the progression to symptomatic type 1 diabetes in people who are in stage 2 of the condition, and will now [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>NIHR funds life-saving treatments and faster diagnosis at BWC</title>
		<link>https://birminghamhealthpartners.co.uk/nihr-funds-life-saving-treatments-and-faster-diagnosis-at-bwc/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Tue, 24 Mar 2026 15:43:15 +0000</pubDate>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Early diagnosis and detection]]></category>
		<category><![CDATA[Experimental medicine]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=11936</guid>

					<description><![CDATA[Funding of £1.5m has been awarded to BHP founder-member Birmingham Women&#8217;s and Children&#8217;s NHS Foundation Trust &#8211; enabling quicker access to life-saving treatments and faster diagnosis of rare and infectious diseases.  This National Institute for Health and Care Research (NIHR) funding boost will be used for two crucial initiatives: building a specialised Aseptic Pharmacy Unit for clinical trials, [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>National childhood type 1 diabetes screening could prevent thousands of emergency diagnoses, Birmingham study shows</title>
		<link>https://birminghamhealthpartners.co.uk/national-childhood-type-1-diabetes-screening-could-prevent-thousands-of-emergency-diagnoses-birmingham-study-shows/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Wed, 21 Jan 2026 12:41:39 +0000</pubDate>
				<category><![CDATA[Birmingham Health Partners]]></category>
		<category><![CDATA[Early diagnosis and detection]]></category>
		<category><![CDATA[Inflammation and chronic disease]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=11840</guid>

					<description><![CDATA[A landmark UK study led by researchers at BHP founder members the University of Birmingham &#8211; which involved tens of thousands of families &#8211; has shown that childhood screening for type 1 diabetes is effective, laying the groundwork for a UK-wide childhood screening programme. Results from the first phase of the ELSA (EarLy Surveillance for [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Simple tool predicts mental health and treatment needs for new inflammatory bowel disease patients</title>
		<link>https://birminghamhealthpartners.co.uk/simple-tool-predicts-mental-health-and-treatment-needs-for-new-inflammatory-bowel-disease-patients/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 10:18:45 +0000</pubDate>
				<category><![CDATA[Early diagnosis and detection]]></category>
		<category><![CDATA[Inflammation and chronic disease]]></category>
		<category><![CDATA[Mental health]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=11836</guid>

					<description><![CDATA[Researchers at BHP founding-members the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, delivered through the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC), have shown how early use of the IBD Disk questionnaire can help forecast which patients are likely to experience more severe physical and mental [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>New trial to test novel diagnostic for bladder cancer recurrence</title>
		<link>https://birminghamhealthpartners.co.uk/new-trail-to-test-novel-diagnostic-for-bladder-cancer-recurrence/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Thu, 28 Aug 2025 11:15:56 +0000</pubDate>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Early diagnosis and detection]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=11442</guid>

					<description><![CDATA[Nonacus, an early cancer testing company, has announced two West Midlands-based trials to assess a new way of monitoring for recurrence of bladder cancer, using a novel test developed in collaboration with researchers from BHP founding-member the University of Birmingham. The at-home urine test uses Nonacus&#8217; highly-sensitive liquid biopsy technology, which was developed in conjunction [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Strict regulations needed to address commercial health self-test concerns</title>
		<link>https://birminghamhealthpartners.co.uk/strict-regulations-needed-to-address-commercial-health-self-test-concerns/</link>
		
		<dc:creator><![CDATA[Louise Stanley]]></dc:creator>
		<pubDate>Mon, 28 Jul 2025 11:51:01 +0000</pubDate>
				<category><![CDATA[Early diagnosis and detection]]></category>
		<guid isPermaLink="false">https://birminghamhealthpartners.co.uk/?p=11424</guid>

					<description><![CDATA[Far greater regulation is needed for off-the-shelf health tests, due to considerable concerns over both suitability of the tests for the public, and accuracy of claims made on-package. In a series of papers published by The BMJ, researchers from BHP founder-member the University of Birmingham funded by the NIHR Birmingham Biomedical Research Centre reviewed a range of commercially-available health [&#8230;]]]></description>
		
		
		
			</item>
	</channel>
</rss>
